Probable leukocytoclastic vasculitis induced by the use of methimazole/ thiamazole
DOI:
https://doi.org/10.11606/issn.2176-7262.rmrp.2025.222566Palabras clave:
Vasculitis leukocytoclastic cutaneous, Methimazole, PharmacovigilanceResumen
The pharmaceutical industry is dedicated to the research, development, manufacture and distribution of drugs for the treatment and prevention of diseases. The development of a drug must go through stages of experimental research and clinical research. It is possible for new drugs to have adverse side effects not observed in experimental research and clinical trials. In Brazil, it is ANVISA's responsibility, through pharmacovigilance, to monitor, identify and evaluate the occurrence of adverse events related to medicines used in the population. In 2012, Biolab Sanus Farmacêutica Ltda launched the drug TAPAZOLE®️ in Brazil for the clinical treatment of hyperthyroidism. In 2018, a 59-year-old woman with hypertension, morbid obesity, asthma, hyperthyroidism, type 2 diabetes mellitus and a diagnosis of invasive basal cell carcinoma on her upper lip was admitted to a private hospital in São Paulo complaining of red spots on her limbs.After the lesions developed into extensive ulcerations, laboratory tests and scientific medical literature showed that the patient had Leukocytoclastic Vasculitis (LV), probably induced by the use of the drug Methimazole/Thiamazole. The condition progressed to extensive ulceration and self-limiting gangrene, with amputation of the 2nd and 3rd fingers and 9 toes. Full recovery occurred after 28 weeks of hospitalization. METHODOLOGY: This is a retrospective case study presenting qualitative data from a real event. Medical records, test results and reports and medical procedures were analyzed. This study was carried out after approval by the UFT Research Ethics Committee - CAAE No. 73029523.5.0000.5519, opinion No. 6.262.298. OBJECTIVE: To report an unusual case of LV probably triggered by the use of the drug Methimazole/Thiamazole. FINAL CONSIDERATIONS: LV is a severe hypersensitivity reaction that may be associated with the continued use of Methimazole/ Thiamazole, a drug used in the clinical treatment of hyperthyroidism. The interaction between the drug and concomitant use with other comorbidities in the human body is not yet fully understood in scientific circles. The duration of use of Methimazole/Thiamazole and the onset of the first symptoms are also unclear.However early withdrawal of the drug could contribute to a positive outcome in these cases.
Descargas
Referencias
1. KATSUNG, B. G et al. Farmacologia básica e clínica. 15° ed. Porto Alegre: McGraw-Hill, 2022. cap. 1, p. 20.
2. BRUNTON, L.L et al. Goodman & Gilman: As Bases Farmacológicas da Terapêutica. 12ª ed. Porto Alegre: McGraw-Hill, 2012. p. 3, 124.
3. BRASIL. Lei n° 9.782, de 26 de janeiro de 1999. Define o Sistema Nacional de Vigilância Sanitária, cria a Agência Nacional de Vigilância Sanitária, e dá outras providências. Diário Oficial da União. Brasilia, 1999. Disponível em: https://www.planalto.gov.br/ccivil_03/leis/l9782.htm#:~:text=LEI%20N%C2%BA%209.782%2C%20DE%2026%20DE%20JANEIRO%20DE%201999.&text=Define%20o%20Sistema%20Nacional%20de,Sanit%C3%A1ria%2C%20e%20d%C3%A1%20outras%20provid%C3%AAncias. Acesso em 8 jun. 2023.
4. TAPAZOL. [Bula]. Taboão da Serra: Biolab Sanus Farmacêutica Ltda. Disponível em: https://consultas.anvisa.gov.br/#/bulario/q/?nomeProduto=TAPAZOL . Acesso em: 8 jun. 2023.
5. De Abrew K, Ayto R, Milnthorpe J. Myeloma-induced leucocytoclastic vasculitis. EJHaem. 2020 Jul 7;1(1):14-15. doi: 10.1002/jha2.32. PMID: 35847737; PMCID: PMC9175879. Disponível em: https://pubmed.ncbi.nlm.nih.gov/35847737/ . Acesso em: 18 fev. 2025.
6. BEZERRA, A. S. et al. Diagnóstico e terapêutica precoce de vasculite leucocitoclástica: relato de caso. Jornal Vascular Brasileiro, v. 19, 2020. Disponível em: https://www.scielo.br/j/jvb/a/Sh8394BB6Dqh8cMYdHPF6Qx/ . Acesso em: 20 fev. 2025.
7. GUCHELAAR, N. A. D. et al. The value of anti-neutrophil cytoplasmic antibodies (ANCA) testing for the diagnosis of ANCA-associated vasculitis, a systematic review and meta-analysis. Autoimmunity Reviews, v. 20, n. 1, p. 102716, jan. 2021. Disponível em: https://www.sciencedirect.com/science/article/pii/S1568997220302950 Acesso em 5 nov. 2023.
8. ISHIZU, A. et al. Expert perspectives on pathological findings in vasculitis. Modern rheumatology, v. 33, n. 1, p. 1–11, 10 maio 2022. Disponível em: https://academic.oup.com/mr/article/33/1/1/6583095 . Acesso em: 20 fev. 2025.
9. GONÇALVES, M. Vasculites: desafio diagnóstico e terapêutico vasculitis: diagnostic and therapeutic challenge. Arq. Catarin Med. 2019 out-dez, v. 48, n. 4, p. 174–190, [s.d.]. Disponível em: https://docs.bvsalud.org/biblioref/2020/01/1048285/531-1838-4-rv.pdf Acesso em 5 nov. 2023.
10. MCPHERSON, R. A.; PINCUS, M. R. Diagnósticos clínicos e tratamento por métodos laboratoriais de Henry, 21° ed. São Paulo, Manole, 2012. p. 128.
11. JAMESON, J. L.; et al. Medicina Interna de Harryson, 20° ed. Porto Alegre, AMGH, 2020. p.1127.
12. FERREIRA, D. S.; COMAR, S. R. Evaluation of mixing tests and the index of circulating anticoagulant in detecting lupus anticoagulants. Jornal Brasileiro de Patologia e Medicina Laboratorial, v. 57, 2021. Disponível em: https://jbpml.org.br/wp-content/uploads/2022/01/10.5935.1676-2444.20210053_PT.pdf Acesso em: 5 nov. 2023.
13.TAWANWOGSRI, W; CHAYAVICHITSILP, P. 2019. Methimazole-Induced Leukocytoclastic Vasculitis: A Case Report. Case report in dermatology. Disponível em: https://doi-org.ez6.periodicos.capes.gov.br/10.1159/000503990 Acesso em: 2 nov. 2023.
14. ARAI, N. et al. Methimazole-induced ANCA-associated vasculitis with diffuse alveolar haemorrhage. Respirology Case Reports, v. 6, n. 5, p. e00315, 8 maio 2018. Disponível em: https://doi-org.ez6.periodicos.capes.gov.br/10.1002/rcr2.315 Acesso em 3 nov. 2023.
15. RIBEIRO, C. DE O. et al. Cutaneous leukocytoclastic vasculitis in the presence of methimazole therapy. Anais Brasileiros de Dermatologia, v. 88, p. 283–286, 1 abr. 2013. Disponível em: https://doi.org/10.1590/S0365-05962013000200021 Acesso em 3 nov. 2023.
16. NEVES, P. D. M. DE M. et al. Methimazole-Induced ANCA Vasculitis: A Case Report. Diagnostics, v. 11, n. 9, p. 1580, 1 set. 2021. Disponível em: https://doi.org/10.3390/diagnostics11091580 Acesso em 4 nov. 2023.
17. SHIKHA, D. et al. Antineutrophilic Cytoplasmic Antibody Positive Vasculitis Associated with Methimazole Use. Case Reports in Endocrinology, v. 2015, p. e530319, 28 abr. 2015. Disponível em: https://doi.org/10.1155/2015/530319 Acesso em 2 nov. 2023
18. NIKITOPOULOU, E.; GAZI, S. Antithyroid drug induced syndrome that lies in between ANCA vasculitis and lupus-like syndrome in a 40-year-old female with Graves’ disease under methimazole therapy: A Case report. Mediterranean Journal of Rheumatology, v. 29, n. 1, p. 52–4, 1 mar. 2018. Disponível em: https://doi.org/10.31138/mjr.29.1.52 Acesso em 3 nov. 2023.
19. HACKING, S. et al. Systemic p-ANCA vasculitis with fatal outcome, arising in the setting of methimazole use. Clinical nephrology - Case studies, v. 7, n. 01, p. 23–26, 16 abr. 2019. Disponível em: doi: 10.5414/CNCS109759 Acesso em 2 nov. 2023.
20. MORITA, T.C.A.B. et al. Atualização em vasculites: visão geral e pontos relevantes dermatológicos para o diagnóstico clínico e histopatológico – Parte I. Disponível em: <https://www.anaisdedermatologia.org.br/pt-pdf-S2666275220301661>. Acesso em 20 fev. 2025.
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2026 Heloi Bruna Ribeiro Melo, Catherine Marie de Campos Menezes Rosa, Marina Rodrigues de Almeida Pinto Ribeiro, Dorival Duarte de Lima, Victor Rodrigues Nepomuceno
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
